FierceBiotech24d
GSK gears up for depemokimab debut with twin FDA filings and phase 3 data dump
With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval ...
Benzinga.com23d
GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
On Saturday, GSK announced full results from the ANCHOR-1 and ANCHOR-2 phase 3 trials of depemokimab versus placebo (both with the standard of care [SOC]) in adults with CRSwNP. ANCHOR-1 (N=271 ...
pharmaphorum2d
ERS: GSK reveals data behind new asthma hope depemokimab
GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...
pharmaphorum6d
GSK asthma hope depemokimab works in second indication
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
Healio13d
Twice-yearly depemokimab for asthma tolerated well as exacerbation rates fall
Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...
Nasdaq23d
GSK: Depemokimab Shows Significant Improvements For CRSwNP Patients In Phase III Trials
(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal ...
Pharm Exec24d
FDA Accepts Biologics License Application for GSK’s Depemokimab for Asthma with Type 2 Inflammation and CRSwNP
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo. The FDA has accepted ...
Investing23d
GSK's depemokimab accepted by FDA for asthma, CRSwNP indications
According to InvestingPro analysis, GSK currently appears undervalued, suggesting potential upside for investors interested in this development. The applications pertain to the use of depemokimab ...